Development of gastroretentive sustained release drug delivery system for certain antibiotic and its in-vitro and in-vivo evaluation / Diena Essam Aboelezz ; Supervised Ahmed Hassan Elhafeey , Yousry Mahmoud Elsayed , Ibrahim Hassan Elsayed
Material type: TextLanguage: English Publication details: Cairo : Diena Essam Aboelezz , 2018Description: 171 P. : charts ; 25cmOther title:- تطوير نظام توصيل محتجز معويا لإطالة مفعول مضاد حيوى وتقييمه معمليا وحيويا [Added title page title]
- Issued also as CD
Item type | Current library | Home library | Call number | Copy number | Status | Date due | Barcode | |
---|---|---|---|---|---|---|---|---|
Thesis | قاعة الرسائل الجامعية - الدور الاول | المكتبة المركزبة الجديدة - جامعة القاهرة | Cai01.08.08.M.Sc.2018.Di.D (Browse shelf(Opens below)) | Not for loan | 01010110075968000 | |||
CD - Rom | مخـــزن الرســائل الجـــامعية - البدروم | المكتبة المركزبة الجديدة - جامعة القاهرة | Cai01.08.08.M.Sc.2018.Di.D (Browse shelf(Opens below)) | 75968.CD | Not for loan | 01020110075968000 |
Browsing المكتبة المركزبة الجديدة - جامعة القاهرة shelves Close shelf browser (Hides shelf browser)
Thesis (M.Sc.) - Cairo University - Faculty of Pharmacy - Department of Pharmaceutics
Gastric retention is designed to prolong gastric residence time of oral controlled release dosage forms. Prolonged contact time of drug with the gastrointestinal mucosa, leads to higher bioavailability, and hence therapeutic efficacy, reduced time intervals for drug administration, potentially reduced dose size and thus improved patient compliance. It helps in sustaining drug delivery mainly for drugs that show site specific absorption from the stomach or the upper intestine. Ofloxacin is a broad-spectrum antimicrobial fluoroquinolone which has activity against a wide range of gram-negative and gram-positive microorganisms. It{u2019}s an off-white to pale yellow crystalline powder. Following oral administration, the bioavailability of ofloxacin in the tablet formulation is approximately 98%. Clearance of ofloxacin is reduced in patients with impaired renal function (creatinine clearance rate <50 mL/min), and dosage adjustment is necessary
Issued also as CD
There are no comments on this title.